Based on the VanEck Bionic Engineering UCITS ETF A Acc GBP stock forecast from 0 analysts, the average analyst target price for VanEck Bionic Engineering UCITS ETF A Acc GBP is not available over the next 12 months. VanEck Bionic Engineering UCITS ETF A Acc GBP’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of VanEck Bionic Engineering UCITS ETF A Acc GBP is Very Bearish, which is based on 0 positive signals and 5 negative signals. At the last closing, VanEck Bionic Engineering UCITS ETF A Acc GBP’s stock price was GBP 16.92. VanEck Bionic Engineering UCITS ETF A Acc GBP’s stock price has changed by -2.66% over the past week, -4.09% over the past month and -87.70% over the last year.
No recent analyst target price found for VanEck Bionic Engineering UCITS ETF A Acc GBP
No recent average analyst rating found for VanEck Bionic Engineering UCITS ETF A Acc GBP
Company Overview VanEck Bionic Engineering UCITS ETF A Acc GBP
CYBG PLC, through its subsidiaries, provides retail and business banking products and services to individuals and businesses under the Clydesdale Bank, Yorkshire Bank, B, and Virgin Money brands in the United Kingdom. It operates through SME Banking and Retail Banking segments. The SME Banking segment offers a range of banking products and services, including business current accounts; and secured and unsecured term loans, business overdrafts, and invoice and asset financing products and services. It also provides international trade services, such as import loans, export loans, documentary collections, currency guarantees, and letters of credit for securing trade; and current account facilities comprising debit cards, cheque books, regular statements, direct debits, and standing orders, as well as day to day and online banking services. This segment serves business customers in the small business, commercial, corporate, and structured finance markets. The Retail Banking segment offers personal current accounts, savings accounts, and term deposits; occupied mortgage loans and BTL loans, unsecured personal loans, and overdrafts, as well as credit card products; and insurance and investment products. The company was founded in 1838 and is based in Glasgow, the United Kingdom. Read Less
CYBG PLC, through its subsidiaries, provides retail and business banking products and services to individuals and businesses under the Clydesdale Bank, Yorkshire Bank, B, and Virgin Money brands in the United Kingdom. It operates through SME Banking and Retail Banking segments. T...Read More
Frequently Asked Questions About VanEck Bionic Engineering UCITS ETF A Acc GBP (CYBG:LSE) Stock
Stock Target Advisor's fundamental analysis for VanEck Bionic Engineering UCITS ETF A Acc GBP's stock is Very Bearish.
Unfortunately we do not have enough data on CYBG:LSE's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on CYBG:LSE's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on CYBG:LSE's stock to indicate if its overvalued.
The last closing price of CYBG:LSE's stock was GBP 16.92.
The most recent market capitalization for CYBG:LSE is GBP 6.05M.
Unfortunately we do not have enough analyst data on CYBG:LSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains VanEck Bionic Engineering UCITS ETF A Acc GBP's stock.
As per our most recent records VanEck Bionic Engineering UCITS ETF A Acc GBP has 0 Employees.
VanEck Bionic Engineering UCITS ETF A Acc GBP's registered address is 20 Merrion Way
LS2 8NZ,Leeds,GBR
.
You can get more information about it from VanEck Bionic Engineering UCITS ETF A Acc GBP's website at http://www.vaneck.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CYBG:LSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
